Mandate

Vinge advises NatWest Markets in connection with a securitisation of secured SME loans

May 19, 2021 Banking and Finance

Vinge has acted for NatWest Markets N.V. as senior lender in the structuring, documenting and execution of a securitisation of secured loans to small and medium sized enterprises (SMEs) granted by DBT Capital AB and its subsidiary (”DBT”), in cooperation with, amongst others, the management of DBT and DBT’s legal advisor. In connection with the securitisation, DBT entered into an up to SEK 1,000,000,000 financing agreement with NatWest Markets as senior lender.

DBT is a Swedish private lender registered with the Swedish Financial Supervisory Authority and who offers corporate loans and financing to SMEs in Sweden.

The transaction is executed and reported under the EU securitisation regulation (Regulation (EU) 2017/2402 of the European Parliament and of the Council of 12 December 2017) and is subject to the reporting requirements thereunder.

Vinge’s team consisted primarily of responsible partner Albert Wållgren together with associates Lionardo Ojeda, Paulina Malmberg, Seyran Sahin, Axel Jansson, Elin Samara and Rebecka Målquist.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025